TR200202103T2 - ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri'' - Google Patents

''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri''

Info

Publication number
TR200202103T2
TR200202103T2 TR2002/02103T TR200202103T TR200202103T2 TR 200202103 T2 TR200202103 T2 TR 200202103T2 TR 2002/02103 T TR2002/02103 T TR 2002/02103T TR 200202103 T TR200202103 T TR 200202103T TR 200202103 T2 TR200202103 T2 TR 200202103T2
Authority
TR
Turkey
Prior art keywords
oxy
naphthyl
methyl
crystals
fluorobenzyl
Prior art date
Application number
TR2002/02103T
Other languages
English (en)
Inventor
Oe Takayuki
Ueno Hiroaki
Maruyama Akira
Masuda Katsuhiko
Original Assignee
Mitsubishi Chemical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corporation filed Critical Mitsubishi Chemical Corporation
Publication of TR200202103T2 publication Critical patent/TR200202103T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)

Abstract

Mevcut bulus, 5-[{6-(2-Flüoro benzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion' un kararli ve yeni B tipi kristallerine iliskin olup, bunlar asagidaki hastaliklarin tedavisine yönelik terapötik ilaçlarda aktif bilesen olarak kullanilmaya uygundur: diyabet ve komplikasyonlari, hiperlipidemi ve komplikasyonlari, hiperürisemi, lösemi ve pankreatit.
TR2002/02103T 1998-11-20 1999-11-19 ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri'' TR200202103T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20

Publications (1)

Publication Number Publication Date
TR200202103T2 true TR200202103T2 (tr) 2002-11-21

Family

ID=18233859

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2002/02109T TR200202109T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri
TR2001/01901T TR200101901T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri
TR2002/02103T TR200202103T2 (tr) 1998-11-20 1999-11-19 ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri''
TR2002/02110T TR200202110T2 (tr) 1998-11-20 1999-11-19 "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TR2002/02109T TR200202109T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri
TR2001/01901T TR200101901T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/02110T TR200202110T2 (tr) 1998-11-20 1999-11-19 "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"

Country Status (23)

Country Link
US (3) US6541493B1 (tr)
EP (1) EP1131310B1 (tr)
JP (1) JP3784001B2 (tr)
KR (1) KR100652326B1 (tr)
CN (1) CN1326449A (tr)
AT (1) ATE315552T1 (tr)
AU (1) AU1185100A (tr)
BR (1) BR9916795A (tr)
CA (1) CA2351727C (tr)
CZ (1) CZ20011763A3 (tr)
DE (1) DE69929476T2 (tr)
ES (1) ES2257104T3 (tr)
HU (1) HUP0104139A3 (tr)
ID (1) ID30064A (tr)
IL (1) IL143177A0 (tr)
NO (1) NO20012444L (tr)
NZ (1) NZ512429A (tr)
PL (1) PL348502A1 (tr)
PT (1) PT1131310E (tr)
TR (4) TR200202109T2 (tr)
TW (2) TWI272944B (tr)
WO (1) WO2000031055A1 (tr)
ZA (1) ZA200104081B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体
MXPA02005008A (es) * 1999-11-19 2003-10-14 Johnson & Johnson Formas de estado solido de 5-((6 -((2-fluorofenil) metoxi)-2 -naftalenil)metil)-2, 4-tiazolidinediona.
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
ES2423991T3 (es) 2008-02-04 2013-09-26 Pfizer Limited Forma polimórfica de un derivado de [1,2,4]triazolo[4,3-a]piridina para el tratamiento de enfermedades inflamatorias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
JP3784001B2 (ja) * 1998-11-20 2006-06-07 三菱化学株式会社 ５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体

Also Published As

Publication number Publication date
PL348502A1 (en) 2002-05-20
TWI272944B (en) 2007-02-11
KR100652326B1 (ko) 2006-11-29
EP1131310A1 (en) 2001-09-12
HUP0104139A2 (hu) 2002-03-28
JP3784001B2 (ja) 2006-06-07
TR200202109T2 (tr) 2002-11-21
CA2351727C (en) 2008-09-23
EP1131310B1 (en) 2006-01-11
WO2000031055A1 (en) 2000-06-02
ZA200104081B (en) 2002-05-20
NZ512429A (en) 2003-11-28
ES2257104T3 (es) 2006-07-16
HUP0104139A3 (en) 2003-12-29
NO20012444D0 (no) 2001-05-18
US20060149075A1 (en) 2006-07-06
TWI250156B (en) 2006-03-01
BR9916795A (pt) 2002-04-09
JP2002530392A (ja) 2002-09-17
DE69929476T2 (de) 2006-09-14
NO20012444L (no) 2001-07-18
TW200613291A (en) 2006-05-01
US20030158241A1 (en) 2003-08-21
CN1326449A (zh) 2001-12-12
KR20010101033A (ko) 2001-11-14
TR200202110T2 (tr) 2002-10-21
CA2351727A1 (en) 2000-06-02
CZ20011763A3 (cs) 2001-10-17
ID30064A (id) 2001-11-01
IL143177A0 (en) 2002-04-21
DE69929476D1 (de) 2006-04-06
TR200101901T2 (tr) 2002-04-22
AU1185100A (en) 2000-06-13
PT1131310E (pt) 2006-05-31
ATE315552T1 (de) 2006-02-15
US6541493B1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE209049T1 (de) Absorbierender artikel
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
WO1999010494A3 (en) Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
TR200201920T2 (tr) İntegrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri.
NZ507203A (en) Use of dexmedetomidine for ICU sedation
JP2004537500A5 (tr)
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
WO2002053090A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
EP1266663A4 (en) EOSINOPHILE SPECIFIC APOPTOSE INDUCTORS
TR200202103T2 (tr) ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri''
DK1343472T3 (da) Thixotropisk næsespray
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
DE69727691D1 (de) Verwendung von keratinocyten-wachstumsfaktor-2
DK0918469T3 (da) Fremgangsmåder og præparater til at øge den vævsanaerobe arbejdskapacitet
ATE270110T1 (de) Arzneimittel enthaltend tissue inhibitor of metalloproteinases-2 (timp-2) als osteoanabol wirksame substanz
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
ATE232541T1 (de) Gallensauersälze mit physiologisch aktiven metalle und ihre verwendung zur therapeutischen behandlung
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
ATE282704T1 (de) Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1)